ライフサイエンスコーパス: premenopausal

1 hormone-releasing hormone [LHRH] agonist if premenopausal).

2 53.3% had received chemotherapy and remained premenopausal.

3 rimary analysis included 1,450 women, mostly premenopausal.

4 iated with lower C-reactive protein (CRP) in premenopausal (-11.5%; 95% CI: -15.0, -8.0; p<0.0001) an

5 trol), the median age was 46 years; 69% were premenopausal, 29% were postmenopausal, and 2% were unkn

6 4 years [range, 25-86 years]; P < .0001), be premenopausal (55 of 86 [64%] vs 349 of 845 [41%], P < .

7 Among premenopausal AA women, comparing variant allele carrier

8 SOFT patients who remained premenopausal after chemotherapy experienced absolute im

9 SOFT patients who remained premenopausal after chemotherapy had an average 5.2% abs

10 Methods In SOFT, women still premenopausal after surgery with or without chemotherapy

11 The growth exclusively at premenopausal ages largely occurred in high-income count

12 Approximately 645 000 premenopausal and 1.4 million postmenopausal breast canc

13 l processing to examine these measures in 45 premenopausal and 10 perimenopausal cycles alongside dat

14 id (FA) storage and FA storage factors in 12 premenopausal and 11 postmenopausal women matched for ag

15 Overall, 4747 (89.8%) premenopausal and 12502 (95.1%) postmenopausal women wit

16 without breast cancer, with a total of 58146 premenopausal and 144600 postmenopausal women enrolled i

17 rotocol, a total of 51 serum samples from 26 premenopausal and 25 postmenopausal women were analyzed.

18 on the PARP; 39.3% (95% CI, 36.6%-42.0%) of premenopausal and 26.2% (95% CI, 24.4%-28.0%) of postmen

19 We included 3,393 premenopausal and 3,915 postmenopausal women with intact

20 We included 3,393 premenopausal and 3,915 postmenopausal women with intact

21 The analysis included 301 premenopausal and 399 postmenopausal breast cancer cases

22 Of 147 patients, 68 (46%) were premenopausal and 79 (54%) were postmenopausal.

23 s the Nation (SWAN) followed 3,302 initially premenopausal and early perimenopausal women from 7 US s

24 , but lower than in men, particularly in the premenopausal and early postmenopausal years.

25 lateral hippocampal connectivity relative to premenopausal and perimenopausal women.

26 linked to an increased incidence of TNBC in premenopausal and postmenopausal African American women.

27 ses, and outcomes and effects in patients at premenopausal and postmenopausal ages.

28 untries with a very high HDI had the highest premenopausal and postmenopausal breast cancer incidence

29 provide evidence of a rising burden of both premenopausal and postmenopausal breast cancer worldwide

30 e time of mammography, and more than half of premenopausal and postmenopausal breast cancers are expl

31 Gender (premenopausal and postmenopausal females), age (prepuber

32 ries with low and medium HDI had the highest premenopausal and postmenopausal mortality, respectively

33 In the IBIS-I randomised controlled trial, premenopausal and postmenopausal women 35-70 years of ag

34 was the most prevalent risk factor for both premenopausal and postmenopausal women and had the large

35 Participants were premenopausal and postmenopausal women who had been diag

36 th clinical breast cancer risk factors among premenopausal and postmenopausal women.

37 breast cancer incidence and mortality among premenopausal and postmenopausal women.

38 ase were not significantly different between premenopausal and postmenopausal women.

39 with lower C-reactive protein levels in both premenopausal and postmenopausal women.

40 ciated with lower C-reactive protein in both premenopausal and postmenopausal women.

41 In all, 4,534 women were premenopausal, and 6,481 postmenopausal, at the time of

42 ce were used as models for adolescent, adult premenopausal, and elderly postmenopausal women, respect

43 Overall, men, premenopausal, and postmenopausal women composed 35.1%,

44 of 203 late-reproductive-age women who were premenopausal at baseline and reached natural menopause.

45 re identified from all participants who were premenopausal at baseline in 1991; over 1.13 million per

46 gen receptor-positive breast cancer who were premenopausal at diagnosis and who underwent chemotherap

47 Women who were premenopausal at the start of follow-up in 1991 were fol

48 cer appeared to be limited to women who were premenopausal at the time of a case [HR=1.07 (95% CI: 1.

49 L incidence in a 5-year prospective study of premenopausal Black women living in Detroit who underwen

50 we observed that women with TNBC had higher premenopausal body mass index and earlier age at first f

51 he inverse association between adult BMI and premenopausal breast cancer (for BMI >/=30 vs. BMI 20-22

52 gher birth length tended to increase risk of premenopausal breast cancer (p for trend = 0.05).

53 in never-smokers (prostate 0.96, 0.93-0.99; premenopausal breast cancer 0.89, 0.85-0.94).

54 isk, both overall (prostate 0.98, 0.95-1.00; premenopausal breast cancer 0.89, 0.86-0.92) and in neve

55 ody shape evolution across life, and risk of premenopausal breast cancer among 406 cases (women aged

56 opment index (HDI) faced a greater burden of premenopausal breast cancer for both new cases and death

57 age-standardised incidence rates (ASIRs) for premenopausal breast cancer in 20 of 44 populations and

58 en maternal weight gain during pregnancy and premenopausal breast cancer incidence in the daughter.

59 ern score had multivariable adjusted HRs for premenopausal breast cancer of 1.35 for adolescent diet

60 (ProBe CaRe) Study, a Danish cohort study of premenopausal breast cancer patients (2002-2011), for wh

61 ole of adiponectin as a potential target for premenopausal breast cancer prevention and treatment.

62 ts a positive association between height and premenopausal breast cancer risk and a negative associat

63 olism are hypothesized to be associated with premenopausal breast cancer risk but evidence is limited

64 he inverse association between adult BMI and premenopausal breast cancer risk may be partially due to

65 ass index (BMI) is inversely associated with premenopausal breast cancer risk, and childhood and adol

66 mated inverse associations with prostate and premenopausal breast cancer risk, both overall (prostate

67 tions between number of nevi and the risk of premenopausal breast cancer, BBD, and family history of

68 es, and coffee may increase the incidence of premenopausal breast cancer.

69 the wives' use was associated primarily with premenopausal breast cancer.

70 We investigated COX-2 regulation in normal premenopausal breast tissue and its relationship to mali

71 ow baseline COX-2 expression is regulated in premenopausal breast tissue because COX-2 levels in norm

72 as associated with an increased incidence of premenopausal but not postmenopausal breast cancer.

73 In premenopausal but not postmenopausal patients with hormo

74 lites and reproductive hormones in a healthy premenopausal cohort and evaluated potential effect modi

75 KRAS variant, compared with 27 (13%) of 201 premenopausal controls (p=0.015).

76 intracardiac anti-fibrotic cytokines, while premenopausal diabetic female rats do not.

77 ower C-reactive protein (CRP) levels in both premenopausal (difference = -11.5%, 95% confidence inter

78 ociated with an earlier age of diagnosis and premenopausal disease.

79 patients (32%; 95% CI, 25% to 39%) developed premenopausal E2 without menses.

80 bly, pre-operative single-agent denosumab in premenopausal early-stage breast cancer patients from th

81 ry is likely linked to the pubertal rise and premenopausal fall of estradiol levels and results in th

82 ascular disease occurs at lower incidence in premenopausal females compared with age-matched males.

83 for sex and up to 41% false discoveries when premenopausal females were not matched for oral contrace

84 prevalence of periodontal diseases among US premenopausal females.

85 with younger age at blood collection, being premenopausal, having an older age at menopause, and nev

86 y was associated with a reduced risk of both premenopausal [hazard ratio (HR) = 0.72, 95% confidence

87 y was associated with a reduced risk of both premenopausal (HR = 0.72, 95% CI, 0.54-0.94) and postmen

88 We examined the relationship between premenopausal hysterectomy and EOC in African-American w

89 3-2001), we investigated the associations of premenopausal hysterectomy and oophorectomy with breast

90 sent; among never users of estrogen-only HT, premenopausal hysterectomy was associated with a signifi

91 Premenopausal hysterectomy was inversely associated with

92 Although research indicates that premenopausal hysterectomy with bilateral oophorectomy d

93 Premenopausal hysterectomy, even without ovary removal,

94 ively, after which they declined, but not to premenopausal levels.

95 similar across menses groups, compared with premenopausal monkeys, peri/postmenopausal monkeys had f

96 ncies to levels comparable to young and aged premenopausal monkeys.

97 A total of 1449 WWH were classified as premenopausal (n = 482) (menses within 12 months; AMH le

98 cases were included, with an oversampling of premenopausal (n = 582) and estrogen receptor-negative (

99 n may result in premature ovarian failure in premenopausal oncology patients.

100 ely provide a means to preserve fertility in premenopausal oncology patients.

101 Age at natural menopause was categorised as premenopausal or perimenopausal, younger than 40 years (

102 oy supplements could be more favorable among premenopausal or recently postmenopausal women deserves

103 c anxiety symptoms among older women who are premenopausal or who consistently take postmenopausal HR

104 The associations were similar for both premenopausal (OR = 0.44, 95% CI:0.31-0.62, p = 9.91 x 1

105 measures and for women who are nonwhite, are premenopausal, or have comorbid conditions were lacking.

106 Postmenopausal and premenopausal patients were 13,686 and 9,482, respective

107 pared with tamoxifen alone for the cohort of premenopausal patients who received prior chemotherapy.

108 ared with no systemic treatment (control) in premenopausal patients with breast cancer over different

109 Premenopausal patients with early breast cancer on the S

110 resulted in a long-term survival benefit in premenopausal patients with estrogen receptor-positive p

111 Premenopausal patients with primary breast cancer (N = 5

112 For evaluation of premenopausal patients, adherence was 63% (overmanagemen

113 logic levels of estradiol, representative of premenopausal patients.

114 generally occurred for physiologic cysts in premenopausal patients; undermanagement was observed for

115 corresponded to the upper half of the normal premenopausal reference range.

116 Women who had not undergone premenopausal reproductive surgery were the referent gro

117 cranial arterial stenosis when compared with premenopausal status in the univariate analysis (OR = 1.

118 Compared with premenopausal status, postmenopausal status is associate

119 beyond five years in both postmenopausal and premenopausal subgroups.

120 Compared with no history of premenopausal surgery, bilateral oophorectomy and hyster

121 rrant adjuvant chemotherapy and who remained premenopausal, the addition of ovarian suppression impro

122 We investigated the influence of premenopausal use of progestogens on melanoma using data

123 isk has been suggested, but the influence of premenopausal use of progestogens on this cancer has nev

124 Premenopausal volunteers (n = 16) underwent imaging week

125 he lactating volunteers as compared with the premenopausal volunteers (P < .005).

126 ed with the group with HRT use (P < .01) and premenopausal volunteers (P < .01) and (b) in the lactat

127 al contraceptives (P = .28-0.82) and between premenopausal volunteers and postmenopausal volunteers w

128 erences in DTI parameters were found between premenopausal volunteers free of oral contraceptives and

129 In all premenopausal volunteers, the DTI parameters exhibited h

130 mone receptor-positive breast cancer and are premenopausal with 5 years of tamoxifen, and those who a

131 n 12 months; AMH level >=20 pg/mL; group 1), premenopausal with reduced ovarian reserve (n = 224) (me

132 rols and transplantated patients compared to premenopausals, with no difference in saliva.

133 in their own clinical practice.A 36-year-old premenopausal woman had been diagnosed with stage III br

134 A 45-year-old premenopausal woman presented with multifocal cancer in

135 Case Report: We report a case of AH in a premenopausal woman presenting with headache.

136 in their own clinical practice.A 46-year-old premenopausal woman with a body mass index of 21 was fou

137 A 42-year-old premenopausal woman with osteogenesis imperfecta present

138 ies (children 9-13 y old, males >/=14 y old, premenopausal women >/=19 y old, and postmenopausal wome

139 Among 2027 premenopausal women (13.1%), biennial screeners had high

140 The association was restricted to premenopausal women (HR = 1.40, ptrend = 0.01), even aft

141 .38; 95% CI, 0.98-5.76, N cases = 50) and in premenopausal women (HR = 3.42; 95% CI, 1.08-10.85).

142 ER(+) cell frequencies, respectively, among premenopausal women (Ki67(hi)/p27(lo): OR = 5.08, 95% CI

143 st association with fat mass was observed in premenopausal women (n = 1192; P = .02).

144 Premenopausal women (n = 27) consumed a choline-sufficie

145 ciated with triple-negative breast cancer in premenopausal women (odds ratio 2.307, 95% CI 1.261-4.21

146 was positively associated with CRP levels in premenopausal women (P < 0.0001).

147 nly OC duration was positively associated in premenopausal women (p<0.0001).

148 ely associated with breast cancer risk among premenopausal women [OR = 10.1, 95% confidence interval

149 fected men aged 40-49 years and HIV-infected premenopausal women aged >/=40 years.

150 actors was 52.7% (95% CI, 49.1%-56.3%) among premenopausal women and 54.7% (95% CI, 46.5%-54.7%) amon

151 the mean (SD) age was 46.3 (3.7) years among premenopausal women and 61.7 (7.2) years among the postm

152 iuria is present in an estimated 1% to 6% of premenopausal women and an estimated 2% to 10% of pregna

153 intake and reproductive hormones in healthy premenopausal women and evaluated the potential effect m

154 age, was lower in postmenopausal compared to premenopausal women and in smokers compared to non-smoke

155 and earlier start and end to childbearing in premenopausal women and obesity in postmenopausal women

156 cancer, and disproportionally affects young premenopausal women and women of African descent.

157 ll sample, but associations were found among premenopausal women and women who consistently took horm

158 Premenopausal women are relatively protected from develo

159 in in breast cancer etiology, yet studies in premenopausal women are scarce.

160 es more favorable tumor characteristics when premenopausal women are screened annually vs biennially.

161 wever, data on its physiologic regulation in premenopausal women are sparse.

162 nd 1.6 (1.0, 2.5) (P = 0.03) for men, having premenopausal women as a reference.

163 nostic effect on recurrence-free survival in premenopausal women at risk for breast cancer.

164 Unlike age-matched men, premenopausal women benefit from cardiovascular protecti

165 ated with a reduced risk of breast cancer in premenopausal women but an increased risk in postmenopau

166 ed follicular estradiol concentrations among premenopausal women but does not appear to affect ovulat

167 Insulin sensitivity is greater in premenopausal women compared with age-matched men, and m

168 ine in renal function in nondiabetic CKD for premenopausal women compared with men.

169 Premenopausal women diagnosed as having breast cancer fo

170 Premenopausal women exhibit enhanced insulin sensitivity

171 study were largely null, it is possible that premenopausal women exposed to passive smoke or carrying

172 risk factors or outcomes based on studies of premenopausal women followed through the menopause trans

173 A total of 259 healthy, premenopausal women from Western New York were followed

174 Premenopausal women had a greater risk of breast cancer

175 Premenopausal women had significantly higher BEC when co

176 These results may help explain why premenopausal women have lower incidence of T2D than age

177 gen metabolites and breast cancer risk among premenopausal women in a case-control study nested withi

178 Fifty premenopausal women living with HIV in Kampala, Uganda,

179 examined the effect in healthy, overweight, premenopausal women of a diet and exercise weight-loss p

180 xcess risk was observed for breast cancer in premenopausal women or for thyroid cancer.

181 n for the primary prevention of fractures in premenopausal women or in men.

182 Postmenopausal women, or premenopausal women receiving a gonadotropin-releasing h

183 In premenopausal women receiving letrozole for neoadjuvant

184 Along this line, premenopausal women seem to be generally protected from

185 Premenopausal women should be advised of the potential e

186 with screening of women ages 40-49 years (or premenopausal women starting at age 40 years) making a n

187 serial breast biopsy analysis in nonpregnant premenopausal women suggested relatively stable baseline

188 (pmol PtdCho-DHA/nmol PtdCho) was higher in premenopausal women than in men and postmenopausal women

189 prevalence of ID and IDA is often greater in premenopausal women than other population demographics.

190 Premenopausal women undergoing commonly used genotoxic (

191 effect on ovarian function and fertility in premenopausal women undergoing treatment for early-stage

192 a in preventing early ovarian dysfunction in premenopausal women undergoing treatment for EBC were se

193 ference in percent MD (PD) between post- and premenopausal women was apparent (-0.46 cm [95% CI: -0.5

194 Twelve healthy Caucasian premenopausal women were compared to a group of healthy

195 In all, 345 premenopausal women were enrolled: 171 on tamoxifen alon

196 Healthy premenopausal women were followed for </=2 menstrual cyc

197 Over an 8-y period (2001-2009), 12,044 premenopausal women were followed for a first diagnosis

198 From 1997 to 2009, 23,580 premenopausal women were followed for incident uterine l

199 A total of 60 healthy, overweight, premenopausal women were included in a 6-mo weight-loss

200 were evaluated in a phase III trial in which premenopausal women were randomly assigned to tamoxifen

201 nd EA regions between the postmenopausal and premenopausal women were significantly different (p = 0.

202 dered standard of care for risk reduction in premenopausal women who are at least 35 years old and ha

203 recurrence score, could be used to identify premenopausal women who could benefit from more effectiv

204 Premenopausal women who first gave birth before age 20 y

205 OR], 4.16; 95% CI, 1.29-13.45; P = .02), and premenopausal women who gave birth to their last child b

206 From December 2008 to August 2011, 58 premenopausal women who had undergone contrast material-

207 y was tamoxifen alone in the majority of the premenopausal women who were 50 years of age or younger.

208 Cases were predominantly premenopausal women who were diagnosed with incident bre

209 We included premenopausal women who were diagnosed with invasive bre

210 ultures of voided midstream urine in healthy premenopausal women with acute uncomplicated cystitis ac

211 Forty premenopausal women with AN and 40 normal-weight women o

212 Premenopausal women with axillary node-negative, hormone

213 Fifty-five men and 85 premenopausal women with BMI 18-24 (lean) and 27-36 kg/m

214 Premenopausal women with breast cancer receiving adjuvan

215 Premenopausal women with breast cancer, and specifically

216 Thirty-four young premenopausal women with early-stage breast cancer who w

217 nt Ovarian Ablation (OA) in the Treatment of Premenopausal Women With Early-Stage Invasive Breast Can

218 Among premenopausal women with either hormone receptor-positiv

219 all genotyped individuals, eight (33%) of 24 premenopausal women with ER/PR-negative cancer had the K

220 east cancer risk in postmenopausal women and premenopausal women with genetic or familial risk factor

221 on Trial (SOFT) showed superior outcomes for premenopausal women with hormone receptor (HR)-positive

222 nvestigated adjuvant endocrine therapies for premenopausal women with hormone receptor-positive breas

223 Premenopausal women with hormone receptor-positive, HER2

224 Between Nov 7, 2003, and April 7, 2011, 4717 premenopausal women with hormone-receptor positive breas

225 In two phase 3 trials, we randomly assigned premenopausal women with hormone-receptor-positive early

226 In premenopausal women with hormone-receptor-positive early

227 Premenopausal women with HR-positive/HER2-negative breas

228 ualize endocrine therapy decision making for premenopausal women with human epidermal growth factor r

229 ns in 1996-1999 and 2007, we ascertained 310 premenopausal women with incident endometriosis and 615

230 r than previous studies and included 102,164 premenopausal women with intact uteri, no prior history

231 ent normal and breast cancer tissues from 96 premenopausal women with known clinical reproductive his

232 In this population of healthy premenopausal women with low exposure levels, cadmium, l

233 We randomly assigned 257 premenopausal women with operable hormone-receptor-negat

234 Premenopausal women with stage cT2 to 4b, any N, M0; est

235 Between October 2003 and January 2008, 281 premenopausal women with stage I to III hormone receptor

236 This ratio was lower in premenopausal women with the rs12325817 polymorphism in

237 ith advanced-stage tumors, and the lowest in premenopausal women with triple-negative cancer.

238 hysterectomy specimens from normally cycling premenopausal women with uterine fibroids, who were not

239 ge at menopause (age at blood collection for premenopausal women) minus age at menarche, subtracting

240 ge at menopause (age at blood collection for premenopausal women) minus age at menarche, years of ora

241 associated with the menstrual status (BEC in premenopausal women, 31.48 +/- 20.68 [standard deviation

242 Participants were 72 healthy premenopausal women, ages 19-52 years, with no current o

243 elopment of triple-negative breast cancer in premenopausal women, and altered gene and miRNA expressi

244 ions were 140.7, 49.4, and 96.7 mg/L in men, premenopausal women, and postmenopausal women, respectiv

245 spine and femoral neck, stratified by male, premenopausal women, and postmenopausal women.

246 Screening of women ages 40-49 years (or premenopausal women, as determined from patient history,

247 gical outcomes associated with ID and IDA in premenopausal women, as the prevalence of ID and IDA is

248 one-receptor-positive early breast cancer in premenopausal women, but its value when added to tamoxif

249 ifen has greater efficacy and can be used in premenopausal women, but raloxifene has fewer side-effec

250 ntaining beverages are widely consumed among premenopausal women, but their association with reproduc

251 In this population of Latin American premenopausal women, different fat distributions in adul

252 For premenopausal women, higher intake of folate was associa

253 al FA, and direct free FA (FFA) storage than premenopausal women, including two-fold greater meal FA

254 breast cancer risk were null, whereas among premenopausal women, nonsignificant positive association

255 Among regularly screened premenopausal women, obesity was not associated with inc

256 ibrosis is greater in postmenopausal than in premenopausal women, perhaps owing to protective effects

257 Evidence suggests that in premenopausal women, sex hormones, particularly estrogen

258 We randomly assigned 3066 premenopausal women, stratified according to prior recei

259 remenstrual syndrome (PMS) affects 15-20% of premenopausal women, substantially reducing quality of l

260 Among premenopausal women, TCDD serum levels were associated w

261 Among premenopausal women, the association with OS was stronge

262 Among premenopausal women, the effect of bariatric surgery was

263 Among premenopausal women, the radicalPD difference per 10-yea

264 For simple cysts in premenopausal women, these thresholds are 3 cm for repor

265 l dysphoric disorder, which affects 2%-5% of premenopausal women, was included in Appendix B of DSMIV

266 ic tachycardia syndrome (POTS) are primarily premenopausal women, which may be attributed to female s

267 inal approach in eight postmenopausal and 25 premenopausal women.

268 targeted biologic therapy, and treatment of premenopausal women.

269 .19 +/- 0.11 vs 0.30 +/- 0.12; P < .05) than premenopausal women.

270 improved menstrual cycle function in healthy premenopausal women.

271 uppression or ablation should be included in premenopausal women.

272 xhibited a pattern of brain activity akin to premenopausal women.

273 eased risk of hepatic fibrosis compared with premenopausal women.

274 factors have been identified, especially for premenopausal women.

275 ared with breast cancers diagnosed in young, premenopausal women.

276 y cycles and sporadic anovulation in healthy premenopausal women.

277 thdrawal and induced hypogonadism in healthy premenopausal women.

278 a cross-sectional study of fibroids in 1152 premenopausal women.

279 e of the results were significant for men or premenopausal women.

280 lead to progression of ER+ breast cancer in premenopausal women.

281 ely associated with breast cancer risk among premenopausal women.

282 lymorphism is responsible for this effect in premenopausal women.

283 luated patterns among regularly menstruating premenopausal women.

284 f anti-estrogen therapies to treat cancer in premenopausal women.

285 tor to disease severity in children, men, or premenopausal women.

286 r risk of second breast neoplastic events in premenopausal women.

287 term habituation in 16 obese and 16 nonobese premenopausal women.

288 us (LBSQ) fat were measured in 28 men and 53 premenopausal women.

289 reast cancer in postmenopausal and high-risk premenopausal women.

290 r for reducing risk of early menopause among premenopausal women.

291 ed with ovarian cancer risk, particularly in premenopausal women.

292 loxifene for breast cancer risk reduction to premenopausal women.

293 strogen therapies, particularly tamoxifen in premenopausal women.

294 nd patient prognosis, most prominently among premenopausal women.

295 EXT, alongside data from the cohort of older premenopausal women.

296 noteworthy associations were observed among premenopausal women.

297 level of symptom burden was similar in older premenopausal women.

298 t but are not worse than those seen in older premenopausal women.

299 n; 27.2%, 17.2%, and 10.6%, respectively, in premenopausal women; and 18.4%, 12.7%, and 10.5%, respec

300 compared with 12.8% of vegetarians in white premenopausal women; P < 0.05 after Bonferroni correctio